SCM
RIGL icon

Sterling Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Sterling Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3K Sell
934
-478
-34% -$16.1K ﹤0.01% 1916
2025
Q4 		$60.5K Buy
1,412
+1,369
+3,184% +$51.6K ﹤0.01% 1732
2025
Q3 		$1.22K Hold
43
– – ﹤0.01% 3052
2025
Q2 		$805 Sell
43
-41
-49% -$777 ﹤0.01% 3092
2025
Q1 		$1.51K Sell
84
-57
-40% -$1.16K ﹤0.01% 2679
2024
Q4 		$2.37K Buy
141
+115
+442% +$2.21K ﹤0.01% 2737
2024
Q3 		$421 Buy
+26
New +$306 ﹤0.01% 2938

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sterling Capital Management's RIGL Position: Q1 2026 in Review

Sterling Capital Management reduced its Rigel Pharmaceuticals (RIGL) stake by 34% in Q1 2026, selling an estimated $16.1K and leaving 934 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

Sterling Capital Management first reported a position in RIGL in Q3 2024 and has held it in 7 quarters since. The position peaked at $60.5K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Sterling Capital Management held 934 shares of Rigel Pharmaceuticals worth $25.3K as of Q1 2026.
  • Sterling Capital Management sold 478 Rigel Pharmaceuticals shares in Q1 2026, an estimated $16.1K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1916 holding.
  • Sterling Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Rigel Pharmaceuticals position peaked at $60.5K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.